New combinations with epirubicin in advanced breast cancer

ONCOLOGY

Volumn 15, Issue 5 SUPPL. 7, 2001, Pages 24-27

  Conte, Pierfranco ^a   Gennari, Alessandra ^a   Landucci, Elisabetta ^a   Guarneri, Valentina ^a   Donati, Sara ^a   Salvadori, Barbara ^a   Bengala, Carmelo ^a   Orlandini, Cinzia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE; DRUG DERIVATIVE; EPIRUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; BREAST TUMOR; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; REVIEW; SURVIVAL RATE; TIME;

ADULT; BREAST NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE; TIME FACTORS;

EID: 0035345104     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3 hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
2. Amadori D, Frassinetti GL, Zoli W, et al: A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Ann Oncol 23 (suppl. 11):16-22, 1996.
3. Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin and paclitaxel vs doxorubicin + paclitaxel as first line therapy for metastatic breast cancer: An intergroup trial (abstract 2). Proc Am Soc Clin Oncol 16:1a, 1997.
4. Valagussa P, Gianni L, Capri G, et al: Three-year follow up in women with metastatic breast cancer after bolus doxorubicin and paclitaxel infused 3 hours (AT) (abstract 429). Proc Am Soc Clin Oncol 17:111, 1998.
5. Conte PF, Baldini E, Gennari A, et al: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15:2510-2517, 1997.
6. Falkson G, Holcroft C, Gelman RS, et al: Ten-year follow up study of premenopausal women with metastatic breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1453-1458, 1995.
7. Rahaman ZU, Frye DK, Smith TL, et al: Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: A reference. Cancer 85:104-111, 1999.
8. Carmichael J, Possinger K, Philip P, et al: Advanced breast cancer: A phase II trial with Gemcitabine. J Clin Oncol 13:2731-2736, 1995.
9. Blackstein M, Vogel CL, Ambinder R, et al: Phase II study of gemcitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:117, 1996.
10. Coates A, Gebski V, Bishop JM, et al: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl Med 317:1490-1495, 1987.
11. Muss HB, Douglas Case L, Richards F, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325:1342-1348, 1991.
12. Ejlertsen B, Pfeiffer P, Pedersen D, et al: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29a:527-531, 1993.
13. Gregory RK, Powles TJ, Chang JC, et al: A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of breast. Eur J Cancer 33:2194-2197, 1997.
14. Janvier M, Spielman M, Nogues C: A randomized trial of maintenance therapy for non metastatic inflammatory breast cancer (abstract 524). Proc Am Soc Clin Oncol 16:150a, 1997.
15. Falkson B, Gelman RS, Pandya KJ, et al: Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16:1669-1676, 1998.
16. Carlson RW, et al: NCCN practice guidelines for breast cancer. Oncology 11 (11A):33-49, 2000.
17. Gennari A, Salvadori B, Donati S, et al: Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors. J Clin Oncol 17:3596-3602, 1999.